Compare ACRV & VIOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACRV | VIOT |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Consumer Electronics/Appliances |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.2M | 65.8M |
| IPO Year | 2022 | 2018 |
| Metric | ACRV | VIOT |
|---|---|---|
| Price | $1.56 | $0.88 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $11.67 | N/A |
| AVG Volume (30 Days) | ★ 343.3K | 266.4K |
| Earning Date | 05-08-2026 | 03-25-2026 |
| Dividend Yield | N/A | ★ 13.49% |
| EPS Growth | ★ 15.13 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $568.17 | $9.04 |
| P/E Ratio | ★ N/A | $3.56 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.15 | $0.87 |
| 52 Week High | $3.56 | $4.33 |
| Indicator | ACRV | VIOT |
|---|---|---|
| Relative Strength Index (RSI) | 47.51 | 35.17 |
| Support Level | $1.56 | N/A |
| Resistance Level | $1.86 | $1.05 |
| Average True Range (ATR) | 0.08 | 0.06 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 76.92 | 0.00 |
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.
Viomi Technology Co Ltd, along with its subsidiaries, specializes in the development and sale of Internet-of-Things-enabled smart home products, particularly focusing on home water solutions. The company markets its products in China and generates the majority of its revenue through the sale of smart water purification systems and other connected home devices designed to improve convenience and automation in residential settings. Its product offerings include water purification products, water heaters, smart water kettles, electric kettles, water filters, range hoods, gas stoves, and other small appliances.